Published in Br J Radiol on December 01, 1975
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol (1985) 3.17
The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) (2001) 1.35
A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol) (1996) 1.31
Fast neutron relative biological effects and implications for charged particle therapy. Br J Radiol (2011) 1.13
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer (1989) 1.12
A four-dimensional computer simulation model of the in vivo response to radiotherapy of glioblastoma multiforme: studies on the effect of clonogenic cell density. Br J Radiol (2006) 1.12
The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol (2003) 1.11
Mathematical models of tumour and normal tissue response. Acta Oncol (1999) 1.07
The assessment of the body distribution of yttrium-90 ferric hydroxide during radiation synovectomy. Br J Radiol (1976) 1.07
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer (1988) 1.06
Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions. Br J Radiol (2006) 1.02
The treatment of uterine carcinoma using the Cathetron. Part I. Technique. Br J Radiol (1967) 0.99
A new remotely controlled unit for the treatment of uterine carcinoma. Lancet (1965) 0.98
A general frmula for equating protracted and acute regimes of radiation. Br J Radiol (1969) 0.96
A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol (2001) 0.91
The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol (2005) 0.89
Comments on Inadequacy of iridium implant as sole radiation treatment for operable breast cancer, Fentiman et al., Eur J Cancer 1996, 32A, pp. 608-611. Eur J Cancer (1997) 0.87
Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes. Phys Med Biol (2010) 0.87
Active minimisation of radiation scatter during breast radiotherapy: management implications for young patients with good-prognosis primary neoplasms. Radiother Oncol (1996) 0.87
The potential impact of relative biological effectiveness uncertainty on charged particle treatment prescriptions. Br J Radiol (2011) 0.87
Cell loss factors and the linear-quadratic model. Radiother Oncol (1995) 0.86
Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.85
Use of second antibody in radioimmunotherapy. NCI Monogr (1987) 0.84
High dose rate brachytherapy practice for the treatment of gynaecological cancers in the UK. Br J Radiol (1999) 0.82
Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) (1997) 0.82
Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol (2008) 0.81
High dose-rate treatment moulds by afterloading techniques. Br J Radiol (1969) 0.81
Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides, with particular reference to iodine-125. Med Phys (1983) 0.81
Particle radiotherapy in the UK. Clin Oncol (R Coll Radiol) (2007) 0.80
Radiobiological modelling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy. Phys Med Biol (2006) 0.80
Results of a questionnaire regarding the practice of radiotherapy for carcinoma of the cervix in the UK. Br J Radiol (1994) 0.80
Estimation of optimum dose per fraction for high LET radiations: implications for proton radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.80
The reduction of tumour control with increasing overall time: mathematical considerations. Br J Radiol (1996) 0.80
The treatment of uterine carcinoma using the Cathetron. Part II. Physical measurements. Br J Radiol (1967) 0.80
Determination of the optimum dose per fraction in fractionated radiotherapy when there is delayed onset of tumour repopulation during treatment. Br J Radiol (2004) 0.80
A critical look at the ret. Br J Radiol (1971) 0.79
Derivation of the optimum dose per fraction from the linear quadratic model. Br J Radiol (1995) 0.79
Radiobiological modeling and clinical trials. Int J Radiat Oncol Biol Phys (2000) 0.79
A graphical method to simplify the application of the linear-quadratic dose-effect equation to fractionated radiotherapy. Br J Radiol (1986) 0.78
Inclusion of molecular biotherapies with radical radiotherapy: modeling of combined modality treatment schedules. Int J Radiat Oncol Biol Phys (1999) 0.78
Repair kinetic considerations in particle beam radiotherapy. Br J Radiol (2011) 0.78
Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer. Br J Cancer (1998) 0.78
Radiobiological compensation of treatment errors in radiotherapy. Br J Radiol (2008) 0.78
The potential of ytterbium 169 in brachytherapy: a brief physical and radiobiological assessment. Br J Radiol (1992) 0.78
Radiobiologically based assessments of the net costs of fractionated focal radiotherapy. Int J Radiat Oncol Biol Phys (1998) 0.77
Pulsed brachytherapy: a modelled consideration of repair parameter uncertainties and their influence on treatment duration extension and daytime-only "block-schemes". Br J Radiol (2011) 0.75
Comment on "Analysis of factors affecting the therapeutic gain in high dose rate gynecological implants relative to low dose rate implants" [Med. Phys. 23, 419-425 (1996)]. Med Phys (1996) 0.75
The BJR and progress in radiobiological modelling. Br J Radiol (2010) 0.75
Regarding Giap and Massullo, IJROBP 1999;45:1355-1358. Int J Radiat Oncol Biol Phys (2000) 0.75
Conventional wisdom and activities of the middle range. Br J Radiol (2005) 0.75
Theoretical implications of incorporating relative biological effectiveness into radiobiological equivalence relationships. Br J Radiol (2013) 0.75
Radiotherapy of carcinoma of the cervix: relevance of dose-rate. Proc R Soc Med (1973) 0.75
The incorporation of specific tissue/nuclide attenuation data into the Anderson method for producing brachytherapy volume-dose histograms. Phys Med Biol (1990) 0.75
Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy. Br J Radiol (2007) 0.75
Proceedings: The advantages of low dose-rate. Br J Radiol (1975) 0.75
Case report: low dose rate and high dose rate intracavitary brachytherapy in a patient with carcinoma of the cervix. Br J Radiol (1996) 0.75
A Monte Carlo derivation of parameters for use in the tissue dosimetry of medium and low energy nuclides. Br J Radiol (1982) 0.75
The sensitizing effect of protracted irradiation. Br J Radiol (1973) 0.75
Implementation of the Philips treatment planning system for use in radiation teletherapy. Br J Radiol (1978) 0.75
Calculation by computer of dose distributions for superficial gold-198 implants and the derivation of optimized distribution rules. Br J Radiol (1976) 0.75
Radial dose function (RDF) Int J Radiat Oncol Biol Phys (1989) 0.75
Modification of the method of Cohen and Scott (1968) to allow for the build-up of sub-lethal damage. Br J Radiol (1969) 0.75
Accelerated fractionation (AF) in head and neck cancers. Radiother Oncol (1998) 0.75
Revisions to radial dose function data for 125I and 131Cs. Med Phys (1987) 0.75
Nominal standard dose and the ret. Br J Radiol (1971) 0.75
Radiobiology of changes in dose-rate. Sonderb Strahlenther Onkol (1988) 0.75
The 1988 BIR award winners. Dr Roger Dale (Röntgen Prize). Br J Radiol (1988) 0.75
Plasma TGFbeta1 during pelvic radiotherapy for gynaecological malignancy. Acta Oncol (2006) 0.75
BED-time charts and their application to the problems of interruptions in external beam radiotherapy treatments. Int J Radiat Oncol Biol Phys (1999) 0.75
A mathematical model of intraluminal and intracavitary brachytherapy. Br J Radiol (1994) 0.75
A Fortran program for fast and compact processing of clinical radiotherapy data. Comput Biol Med (1984) 0.75
Implications of overall time in radiotherapy. Clin Oncol (R Coll Radiol) (1993) 0.75
Estimation of tumour hypoxic fraction from clinical data sets compatible with accelerated repopulation. Acta Oncol (1998) 0.75
Exit dose studies in megavoltage photon therapy. Br J Radiol (1983) 0.75
A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90. Phys Med Biol (2006) 0.75
Quality control of linear accelerator x-ray performance using semiconductor probes. Radiology (1985) 0.75